A citation-based method for searching scientific literature

Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
Times Cited: 9







List of co-cited articles
68 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
226
55

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
113
44

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
Chantal Mathieu, Paresh Dandona, Andreas L Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus Florian Scheerer, Fredrik Thoren, Moshe Phillip. Diabetes Obes Metab 2020
16
44

The mechanisms of action of metformin.
Graham Rena, D Grahame Hardie, Ewan R Pearson. Diabetologia 2017
882
33

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
143
33

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
113
33

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
144
33

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
139
33

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
93
33


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
22

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
12
22


Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
6
33


Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
10
22

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
Paolo Pozzilli, Richard D Leslie, Anne L Peters, Raffaella Buzzetti, Sudha S Shankar, Zvonko Milicevic, Imre Pavo, Jeremie Lebrec, Sherry Martin, Nanette C Schloot. Diabetes Obes Metab 2018
26
22

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
87
22

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
39
22

Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Marie-Christine Dubé, Martin D'Amours, S John Weisnagel. Diabetes Obes Metab 2018
17
22

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
176
22

Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
Frederik Staels, Carolien Moyson, Chantal Mathieu. Diabetes Obes Metab 2017
17
22

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
22


SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
39
22

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
22

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
22

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
22

β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.
Carmella Evans-Molina, Emily K Sims, Linda A DiMeglio, Heba M Ismail, Andrea K Steck, Jerry P Palmer, Jeffrey P Krischer, Susan Geyer, Ping Xu, Jay M Sosenko. JCI Insight 2018
47
22


SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Halis Kaan Akturk, Amanda Rewers, Satish K Garg. Curr Opin Endocrinol Diabetes Obes 2018
9
22

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
978
22

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
25
22


Glycemic control and excess mortality in type 1 diabetes.
Marcus Lind, Ann-Marie Svensson, Mikhail Kosiborod, Soffia Gudbjörnsdottir, Aldina Pivodic, Hans Wedel, Sofia Dahlqvist, Mark Clements, Annika Rosengren. N Engl J Med 2014
502
22

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven Edelman, Johan Jendle, John Xu, Markus F Scheerer, Fredrik Thoren, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2020
20
22

Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement.
Ernesto Maddaloni, Nader Lessan, Alia Al Tikriti, Raffaella Buzzetti, Paolo Pozzilli, Maha T Barakat. PLoS One 2015
53
22


The many faces of diabetes: a disease with increasing heterogeneity.
Tiinamaija Tuomi, Nicola Santoro, Sonia Caprio, Mengyin Cai, Jianping Weng, Leif Groop. Lancet 2014
345
22

High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7).
Simona Zampetti, Giuseppe Campagna, Claudio Tiberti, Marco Songini, Maria Luisa Arpi, Giuseppina De Simone, Efisio Cossu, Lorenzo Cocco, John Osborn, Emanuele Bosi,[...]. Eur J Endocrinol 2014
45
22

Adult-onset autoimmune diabetes in 2020: An update.
Ernesto Maddaloni, Chiara Moretti, Carmen Mignogna, Raffaella Buzzetti. Maturitas 2020
11
22

The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
Antonio Petrone, Concetta Suraci, Marco Capizzi, Andrea Giaccari, Emanuele Bosi, Claudio Tiberti, Efisio Cossu, Paolo Pozzilli, Alberto Falorni, Raffaella Buzzetti. Diabetes Care 2008
51
22

Impact of obesity on the increasing incidence of type 1 diabetes.
Raffaella Buzzetti, Simona Zampetti, Paolo Pozzilli. Diabetes Obes Metab 2020
17
22


Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).
Ernesto Maddaloni, Ruth L Coleman, Paolo Pozzilli, Rury R Holman. Diabetes Obes Metab 2019
20
22

Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.
Angus G Jones, Timothy J McDonald, Beverley M Shields, Anita V Hill, Christopher J Hyde, Bridget A Knight, Andrew T Hattersley. Diabetes Care 2016
89
22


The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Richard I G Holt, J Hans DeVries, Amy Hess-Fischl, Irl B Hirsch, M Sue Kirkman, Tomasz Klupa, Barbara Ludwig, Kirsten Nørgaard, Jeremy Pettus, Eric Renard,[...]. Diabetes Care 2021
37
22

Adult-onset autoimmune diabetes: current knowledge and implications for management.
Raffaella Buzzetti, Simona Zampetti, Ernesto Maddaloni. Nat Rev Endocrinol 2017
110
22

Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study.
Zhiguang Zhou, Yufei Xiang, Linong Ji, Weiping Jia, Guang Ning, Gan Huang, Lin Yang, Jian Lin, Zhenqi Liu, William A Hagopian,[...]. Diabetes 2013
165
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.